CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Pembrolizumab 100 MG Injectiondrug
Likely dose
Pembrolizumab 100 MG Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05023837
NCT05023837N/ACompleted
CompareCT.gov

Evaluation of the Efficacy of Immunotherapy in Uncommon Pathological Types of Lung Cancer

Hunan Province Tumor Hospital·observational·Posted Aug 27, 2021·Updated Jan 25, 2022

In Brief

An observational study evaluating Pembrolizumab 100 MG Injection for Uncommon Pathological Types of Lung Cancer. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study was designed to explore the efficacy and safety of immune checkpoint inhibitor for advanced uncommon pathological types of lung cancer whether or not it is accompanied by a driver mutationin the real world. Through retrospective collection of clinical data of patients with uncommon pathological types of lung cancer.The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUncommon Pathological Types of Lung Cancer
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 27, 2021
Enrollment StartMar 2, 2018
Primary CompletionAug 2, 2021
Study CompletionAug 3, 2021
TodayJul 1, 2026
Enrollment to primary: 3.4 yearsPosted 4.8 years ago

Interventions

Pembrolizumab 100 MG Injectiondrug

Pembrolizumab iv 200mg q21d